Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

NCT04052555 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

42

Enrollment

NIH

Sponsor class

Conditions

Bilateral Breast Carcinoma
HER2-Negative Breast Carcinoma
Localized Breast Carcinoma
Recurrent Breast Carcinoma
Triple-Negative Breast Carcinoma

Interventions

DRUG: Berzosertib
PROCEDURE: Biospecimen Collection
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
RADIATION: Radiation Therapy

Sponsor

National Cancer Institute (NCI)